Dr. Steven M. Fruchtman has been appointed president of Onconova Therapeutics, Inc., a late-stage biopharma company with a primary focus on myelodysplastic syndromes (MDS). Dr. Fruchtman will have oversight over the entire product portfolio, as well as a key role in all other areas of the company. He will maintain the responsibilities of chief medical officer until a replacement is named. Dr. Fruchtman will continue to report to Dr. Ramesh Kumar, co-founder and chief executive officer of the ...